Opendata, web and dolomites

NovInDXS SIGNED

Development of novel inhibitors of the anti-infective target DXS using dynamic combinatorial chemistry (DCC)

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NovInDXS project word cloud

Explore the words cloud of the NovInDXS project. It provides you a very rough idea of what is the project "NovInDXS" about.

combinatorial    entirely    urgently    hit    staphylococcus    biochemical    cell    assays    despite    agents    vivo    plasmodium    candidate    inhibitors    time    economical    infective    pathogens    erythritol    action    tested    fulfil    hitherto    phosphate    discovery    first    anti    hence    ideal    methicillin    blocks    drug    substantial    medically    parts    idnetifiying    strategy    building    alarming    aeruginosa    maximise    tuberculosis    efforts    emergence    2c    potent    chemical    heterocycles    chances    situation    chiral    health    active    bacterial    falciparum    dxs    candidates    dynamic    dcc    unprecedented    chemistry    explore    benefits    care    few    heterocyclic    compounds    serious    enzyme    none    identification    absent    space    selective    resistant    union    mycobacterium    date    globally    methyl    pseudomonas    aureus    scaffolds    unexplored    bacteria    underexplored    global    mode    pioneer    humans    reported    socio   

Project "NovInDXS" data sheet

The following table provides information about the project.

Coordinator
HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH 

Organization address
address: INHOFFENSTRASSE 7
city: BRAUNSCHWEIG
postcode: 38124
website: www.helmholtz-hzi.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 171˙460 €
 EC max contribution 171˙460 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2018
 Duration (year-month-day) from 2018-03-01   to  2020-05-26

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH DE (BRAUNSCHWEIG) coordinator 171˙460.00

Map

 Project objective

The emergence of multi-drug resistant pathogens is a serious global problem. In this alarming situation, novel targets for which inhibitors with an unprecedented mode of action can be developed are urgently required. This proposal aims at the development of selective and potent inhibitors of the important and underexplored anti-infective target DXS, an enzyme from the 2C-methyl-D-erythritol 4-phosphate pathway that is entirely absent in humans but is essential for medically relevant pathogens (e.g., Plasmodium falciparum, Mycobacterium tuberculosis, Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus). Despite substantial efforts dedicated to the discovery of inhibitors for DXS, to date very few active compounds have been reported and none of them fulfil the requirements as an ideal candidate for further development. To address these issues and maximise the chances of success, we will use dynamic combinatorial chemistry (DCC) as a hit identification strategy for the first time for the enzyme-DXS. To explore hitherto unexplored parts of the chemical space, we will pioneer the use of chiral heterocyclic building blocks in DCC for the discovery of potent inhibitors of the enzyme DXS. Use of chiral heterocycles in DCC will allow to rapidly access novel scaffolds. These chiral heterocyclic scaffolds will be evaluated for their biochemical activity on bacterial DXS. The most promising candidates will be tested in in vivo cell-based assays in bacteria. The proposed approach for the design of chiral heterocyclic inhibitors for novel targets such as the enzyme DXS will enhance the knowledge about this underexplored target and will open up access to various potent inhibitors. Hence, this research programme will greatly improve the chances of idnetifiying new anti-infective agents with a novel mode of action, leading to socio-economical benefits for the health care sector in the European Union and also globally.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NOVINDXS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NOVINDXS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MultiSeaSpace (2019)

Developing a unified spatial modelling strategy that accounts for interactions between species at different marine trophic levels, and different types of survey data.

Read More  

ASSEMBLY (2019)

Advancing Synthethic Supramolecular chemical biology

Read More  

TxnEvoClim (2019)

Climate adaptation in Arabidopsis thaliana through evolution of transcription regulation

Read More